Page 1

BT INFANT BACTERIAL THERAPEUTICS Infant Bacterial Therapeutics AB ( publ ) Interim report January 1 - March 31 , 2021 First quarter ( Jan - Mar ) 2021 • Net sales 0 KSEK ( 0 ) • Operating income 452 KSEK * ( 1 206 ) • Earnings per share before and after dilution 0.04 . ( SEK ) 0.10 * Operational income includes exchange rate gains on foreign currency deposits for the purpose of securing future outflows amounting to 12 114 ( 13 857 ) KSEK . Significant events during the first quarter ( Jan - Mar ) 2021 • On February 9 , we announced that the Japan Patent Office has issued a decision to grant a patent entitled : " A method of activating lactic acid bacteria " , which protects the formulation of Lactobacillus reuteri including IBP - 9414 . The Japanese patent is valid until 2036 and IBP - 9414 is intended for marketing in Japan upon market approval .. • On February 10 , we announced that the company has reached an important milestone after recruiting 300 premature infants to the ongoing clinical Phase III study of IBP - 9414 . This also means that a safety analysis of these infants will take place in order to also recruit infants with a very low birth weight , which in turn is expected to significantly increase the recruitment rate . Furthermore it means that IBT has an opportunity to validate the study's second primary endpoint , " feeding tolerance " , and redefine this if necessary . • In response to the COVID - 19 pandemic and the coronavirus , IBT is closely monitoring developments and is actively taking measures to minimize or limit affects thereof on the company's operations . IBT adheres to directives issued by Folkhälsomyndigheten , the WHO and ECDC ( European center for prevention and control of disease ) . The pandemic affects the recruitment level in IBT's pivotal study , " The Connection study " . The bulk of the costs for conducting the study are generated in connection with recruitment of patients , and thus the assessment is that IBT has sufficient funds to conclude the study even if this occurs at a later point in time than originally planned . Significant events after the reporting period • On April 15 , we announced that the Chinese Patent Office has issued a decision to grant a patent entitled : " A method of activating lactic acid bacteria " , which protects the formulation of Lactobacillus reuteri . The Chinese patent is valid until 2036 and IBP - 9414 is intended for marketing in China upon market approval . • On April 29 , we announced that inclusion criteria of The Connection Study has been expanded to include 500 - 1000 gram birth weight premature infants ( from earlier 750-1000 grams ) after the Data Monitoring Committees ' planned review of study data . Since April 29 , infants in this weight group have been recruited . Selected financial data 000's Net sales Other income , KSEK Operating profit / loss , KSEK Result after tax , KSEK Total assets , KSEK Cash flow for the period , KSEK Cash flow per share for the period ( SEK ) Cash , KSEK Earnings per share before and after dilution ( SEK ) Equity per share ( SEK ) Equity ratio ( % ) Infant Bacterial Therapeutics AB ( publ ) 2021 Jan - Mar 64 452 451 451 138 -9 794 -0.87 425 758 0.04 39.26 98 % 2020 Jan - Mar 75 1 206 1 178 523 168 -8 050 -0.72 500 995 -0.10 45.57 98 % 2020 Jan - Dec -71918 -72 007 450 318 -56 625 -5.04 423 438 -6.41 39.21 98 % Interim report January 1- March 31 , 2021 1